Zydus Lifesciences has reported positive top-line results from EVIDENCES-X, a 52-week Phase II(b) study of its drug Saroglitazar Magnesium in patients with metabolic dysfunction associated steatohepatitis, a serious form of fatty liver disease known as MASH. The company said the trial met its main goal, with the drug clearing liver inflammation and cell damage more effectively than a placebo without making liver scarring worse. The result is an early but meaningful signal in a field where approved treatment options remain scarce.
Main outcomes from the EVIDENCES-X study
- Zydus Lifesciences announced top-line findings from its 52-week Phase II(b) EVIDENCES-X trial evaluating Saroglitazar Mg for metabolic dysfunction associated steatohepatitis (MASH).
- The study met its primary endpoint, demonstrating a 26.5% treatment difference compared with placebo in resolving steatohepatitis without worsening liver fibrosis.
- The trial examined 189 randomized subjects across research centers in the United States, Turkey, and Argentina.
- Saroglitazar Mg received regulatory approval in India from the Drug Controller General of India (DCGI) in 2020, but remains an investigational therapy in the United States and Europe.
| Finding | Plain-English meaning |
|---|---|
| Saroglitazar Mg achieved a 26.5% treatment difference over placebo in resolving steatohepatitis without worsening fibrosis at week 52. | The medication cleared liver inflammation and cell damage noticeably better than a dummy pill after one year without causing further scar tissue build-up. |
| The EVIDENCES-X trial enrolled 189 subjects across the United States, Turkey, and Argentina. | Researchers tested the therapy on 189 participants across three countries to evaluate its effects across distinct regional groups. |
| DCGI approved Saroglitazar Mg in India in 2020, while the drug remains investigational under the FDA and EMA. | Regulators in India approved the therapy six years ago, but medical agencies in the United States and Europe still treat it as experimental pending further testing. |
Trial parameters and outcome metrics
| Parameter | Trial details |
|---|---|
| Lead Sponsor | Zydus Lifesciences Limited |
| Investigational Agent | Saroglitazar Magnesium (Saroglitazar Mg) |
| Trial Designation | EVIDENCES-X (Phase II(b)) |
| Total Enrollment | 189 subjects |
| Trial Locations | United States, Turkey, Argentina |
| Randomization Ratio | 1:1:1 (2 mg dose, 4 mg dose, placebo) |
| Duration of Treatment | 52 weeks |
What the trial measured
The primary endpoint of EVIDENCES-X was resolution of steatohepatitis with no worsening of fibrosis, confirmed by liver biopsy at week 52. In plain terms, the researchers wanted to see the inflammation and liver cell injury that define MASH disappear, while the scar tissue known as fibrosis stayed at least stable rather than advancing. This is a demanding, biopsy-confirmed standard rather than a blood test, and it is the same type of endpoint that regulators have used to judge other liver drugs, which makes a clear separation from placebo notable.
Across the 189 participants, Saroglitazar Mg produced a 26.5% treatment difference over placebo on that endpoint. The study was designed so that patients received either a 2 mg dose, a 4 mg dose, or a placebo in equal numbers, and it was double-blind, meaning neither the patients nor the treating doctors knew who was on the active drug. That design helps guard against the expectation effects that can distort results in trials of chronic disease.
Zydus also reported that secondary and exploratory measures pointed in the same direction, with improvements seen in liver histology components such as fat accumulation, inflammation, and hepatocyte ballooning, the swelling of liver cells that is a hallmark of the disease. Those findings support the primary result, though the company has not yet released the underlying figures.
Why MASH is a hard problem
MASH sits at the severe end of a spectrum of fatty liver disease. The broader condition, metabolic dysfunction associated steatotic liver disease, or MASLD, affects roughly a quarter of adults worldwide, and a substantial subset of those people progress to MASH, where fat is joined by active inflammation and cell damage. Estimates place the global adult prevalence of MASH itself in the range of 5% to 20%. Because the disease is closely tied to obesity, type 2 diabetes, and insulin resistance, its burden has risen alongside those conditions.
The danger of MASH is what it can lead to. Sustained inflammation drives fibrosis, and advancing fibrosis can end in cirrhosis, liver failure, and hepatocellular carcinoma, the most common form of liver cancer. Fibrosis stage is widely regarded as the strongest predictor of long-term outcomes in these patients. Yet for years the treatment cupboard has been nearly bare, with management resting largely on weight loss and control of the underlying metabolic drivers rather than on drugs that act directly on the liver. That gap is what makes any positive Phase II(b) readout in this space worth attention.
Investigators and company response
The study was led by two well-known hepatology researchers serving as principal investigators, Prof. Naga Chalasani of the Indiana University School of Medicine and Prof. Arun J. Sanyal of Virginia Commonwealth University, both long associated with liver disease trials. Their involvement lends the program credibility within the specialist community.
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, framed the readout as a step forward for the company’s liver disease work. “These results reinforce the therapeutic potential of Saroglitazar Mg and our commitment to developing innovative treatment options for patients suffering from chronic liver diseases,” he said.
Saroglitazar Mg is not a new molecule. It is already approved in India, where the DCGI cleared it in 2020 for MASH and MASLD, and the company has commercial experience with the drug there. What EVIDENCES-X adds is controlled, biopsy-based evidence generated across multiple countries, the kind of data that regulators in the United States and Europe expect before considering approval. In those markets the drug remains investigational.
What comes next
The announcement is a top-line summary, not the full dataset, and several important details are still outstanding. The company has not disaggregated how the 2 mg and 4 mg doses performed relative to each other, nor has it published the detailed safety profile, including side effects, serious adverse events, and how many participants left the study early. Those numbers will matter for judging whether the benefit seen on biopsy comes at an acceptable cost.
Zydus said the complete results will be presented at an upcoming scientific conference and submitted for peer-reviewed publication, the standard route for data that could eventually support regulatory filings. A positive Phase II(b) result does not guarantee success in the larger Phase III trials that typically follow, and the history of MASH drug development is littered with candidates that stumbled at that stage. For now, the EVIDENCES-X readout keeps Saroglitazar Mg in the conversation as a potential treatment for a common disease that still has few good options.
Related Coverage
Sources:
- Zydus reports positive Phase II(b) MASH trial results for Saroglitazar, achieves primary endpoint, Medical Dialogues
- Update on Clinical Trials for Nonalcoholic Steatohepatitis (Nathani & Bansal, 2023), Gastroenterology & Hepatology
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.